Skip to main content
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 2016 Apr 1;126(4):1603. doi: 10.1172/JCI87345

The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells

Rosa Marina Melillo, Maria Domenica Castellone, Valentina Guarino, Valentina De Falco, Anna Maria Cirafici, Giuliana Salvatore, Fiorina Caiazzo, Fulvio Basolo, Riccardo Giannini, Mogens Kruhoffer, Torben Orntoft, Alfredo Fusco, Massimo Santoro
PMCID: PMC4811160  PMID: 27035814

Original citation: J Clin Invest. 2005;115(4):1068–1081. doi:10.1172/JCI22758.

Citation for this retraction: J Clin Invest. 2016;126(4):1603. doi:10.1172/JCI87345.

At the request of the corresponding author, the JCI is retracting this manuscript. The corresponding author recently notified the JCI that multiple microscopy images in Figure 2B were previously published and were used to represent different samples in another publication by the corresponding author’s group (1). The authors have stated that experimental data produced ad hoc are consistent with those in the original publication; however, the paper is being retracted due to data duplication and misrepresentation in the original publication.

Footnotes

See the related article beginning on page 1068.

References

  • 1.Melillo RM, et al. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. Am J Pathol. 2004;165(2):511–521. doi: 10.1016/S0002-9440(10)63316-0. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES